Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the determination of the novel proteasome inhibitor CEP-18770 in human plasma and its application in a clinical pharmacokinetic study

Journal of Mass Spectrometry

Volumn 45, Issue 11, 2010, Pages 1299-1305

  Sala, Federica ^a   Marangon, Elena ^a   Bagnati, Renzo ^a   Livi, Valeria ^b   Cereda, Roberta ^b   D'Incalci, Maurizio ^a   Zucchetti, Massimo ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b EOS   (Italy)

Author keywords

CEP 18770; HPLC MS MS; human pharmacokinetics; Phase I study; proteasome inhibitor

Indexed keywords

CEP-18770; HPLC-MS/MS; HUMAN PHARMACOKINETICS; PHASE I; PROTEASOME INHIBITORS;

ACETONITRILE; CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIQUIDS; MASS SPECTROMETRY; PLASMA (HUMAN);

PHARMACOKINETICS;

ACETONITRILE; BORONIC ACID DERIVATIVE; CEP 18770; IRBESARTAN; PROTEASOME INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER PATIENT; CLINICAL EVALUATION; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MULTIPLE MYELOMA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STANDARD; TANDEM MASS SPECTROMETRY;

ACETONITRILES; BIPHENYL COMPOUNDS; BORONIC ACIDS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLINICAL TRIALS, PHASE I AS TOPIC; DRUG STABILITY; HUMANS; MULTIPLE MYELOMA; NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; TETRAZOLES; THREONINE;

EID: 78649593066     PISSN: 10765174     EISSN: 10969888     Source Type: Journal    
DOI: 10.1002/jms.1842     Document Type: Article

References (16)

1. P. M. Voorhees, E. C. Dees, B. O'Neil, R. Z. Orlowski,. The proteasome as a target for cancer therapy. Clin Cancer Res. 2003, 9, 6316.
2. S. V. Rajkumar, P. G. Richardson, T. Hideshima, K. C. Anderson,. Proteasome inhibition as a novel therapeutic target in human cancer. J. Clin. Oncol. 2005, 19, 630.
3. P. G. Richardson, P. Sonneveld, M. Schuster, D. Irwin, E. Stadtmauer, T. Facon, J. L. Harousseau, D. Ben-Yehuda, S. Lonial, H. Goldschmidt, D. Reece, J. San Miguel, J. Bladé, M. Boccadoro, J. Cavenagh, M. Alsina, S. V. Rajkumar, M. Lacy, A. Jakubowiak, W. Dalton, A. Boral, D. L. Esseltine, D. Schenkein, K. C. Anderson,. Extended follow-up of a Phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007, 110, 3557.
4. A. Belch, C. T. Kouroukis, M. Crump, L. Sehn, R. D. Gascoyne, R. Klasa, J. Powers, J. Wriqt, E. A. Eisenhauer,. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann. Oncol. 2007, 18, 116.
5. M. P. Curran, K. McKeage,. Bortezomib: a review of its use in patients with multiple myeloma. Drugs 2009, 69, 859.
6. L. R. Dick, P. E. Fleming,. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov. Today 2010, 15, 243.
7. B. D. Dorsey, M. Iqbal, S. Chatterjee, E. Menta, R. Bernardini, A. Bernareggi, P. G. Cassarà, G. D'Arasmo, E. Ferretti, S. De Munari, A. Oliva, G. Pezzoni, C. Allievi, I. Strepponi, B. Ruggeri, M. A. Ator, M. Williams, J. P. Mallamo,. Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer. J. Med. Chem. 2008, 51, 1068.
8. R. Piva, B. Ruggeri, M. Williams, G. Costa, I. Tamagno, D. Ferrero, V. Giai, M. Coscia, S. Peola, M. Massaia, G. Pezzoni, C. Allievi, N. Pescalli, M. Cassin, S. di Giovine, P. Nicoli, P. de Feudis, I. Strepponi, I. Roato, R. Ferracini, B. Bussolati, G. Camussi, S. Jones-Bolin, K. Hunter, H. Zhao, A. Neri, A. Palumbo, C. Berkers, H. Ovaa, A. Bernareggi, G. Inghirami,. CEP-18770: a novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood 2008, 111, 2765.
9. D. J. Nix, C. Pien, J. LaButti, T. Maden, J. Adams, P. Elliott,. Clinical pharmacology of the proteasome inhibitor PS-341. Proceedings of the 2001 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 7, 11, 2001, (abstract 389).
10. D. Leveque, M. C. Carvalho, F. Maloisel,. Review. Clinical pharmacokinetics of bortezomib. In Vivo 2007, 2, 273.
11. T. M. Horton, D. Pati, S. E. Plon, P. A. Thompson, L. M. Bomgaars, P. C. Adamson, A. M. Ingle, J. Wright, A. H. Brockman, M. Paton, S. M. Blaney,. A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group Study. Clin. Cancer Res. 2007, 13, 1516.
12. K. Venkatakrishnan, M. Rader, R. K. Ramanathan, S. Ramalingam, E. Chen, W. Riordan, W. Trepicchio, M. Cooper, M. Karol, L. von Moltke, R. Neuwirth, M. Egorin, G. Chatta,. Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study. Clin. Ther. 2009, 31, 2444.
13. U.S. Food and Drug Administration: Center for Drug Evaluation and Research (CDER). Guidance for Industry Bioanalytical Method Validation. (May 2001). Available:.
14. C. T. Viswanathan, S. Bansal, B. Booth, A. J. DeStefano, M. J. Rose, J. Sailstad, V. P. Shah, J. P. Skelly, P. G. Swann, R. Weiner,. Pharm. Res. 2007, 24, 1962.
15. D. M. Fast, M. Kelley, C. T. Viswanathan, J. O'Shaughnessy, S. King, A. Chaudhary, R. Weiner, A. De Stefano, D. Tang,. Workshop report and follow-up-AAPS Workshop on current topics in GLP bioanalysis: Assay reproducibility for incurred samples-implications of Crystal City recommendations. AAPS J. 2009, 11, 234.
16. D. E. Reece, D. Sullivan, S. Lonial, A. F. Mohrbacher, G. Chatta, C. Shustik, H. Burris, K. Venkatakrishnan, R. Neuwirth, W. J. Riordan, M. Karol, L. L. von Moltke, M. Acharya, P. Zannikos, A. Keith Stewart,. Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma. Cancer Chemother. Pharmacol. 2010, (in press).